AI predicts lung boost from obesity drugs
NCT ID NCT07663591
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how incretin-based therapies (like GLP-1 drugs used for weight loss) affect breathing in people with obesity. Researchers will analyze data from 48 adults aged 25-60 with a BMI of 30 or higher. They will use machine learning to find patterns that predict improvements in lung function and respiratory muscle strength.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- incretin-based therapy (a class of diabetes/weight-loss drugs like GLP-1 agonists)
- What this could lead to
- If successful, this could help doctors predict which patients with obesity will see the most improvement in breathing after incretin-based therapy.
- What could go wrong
- This is a small, early-stage analysis of existing data, not a new treatment trial. Results may not apply to everyone, and the study hasn't started recruiting yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY (BMI>30) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Weight-Loss drug ease chronic back pain? a trial investigates
- Exercise plus taurine may fight hidden muscle fat in older women
- MRI reveals hidden body changes after Weight-Loss surgery
- Could exercise boost taurine in older women with obesity?
- Three-Day fast reshapes fat cells and boosts fat burning, study hints
- Swallowable balloon offers Non-Surgical weight loss hope